Results
|
|
1.
|
Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review. [Review] MedStar authors:
Year: 2022
Citation: - Clinical lymphoma, myeloma & leukemia. 22(5):e285-e292, 2022 05.
Department: - MedStar Health Baltimore Residents
Medline publication type:
All authors: - Ansar I, Ehsan A, Ehsan H, Hashmi H, Masood A, Neupane K, Rafae A, Sana MK, Umar A, Wahab A
|
|
|
2.
|
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. MedStar authors:
Year: 2019
Citation: - Lancet Oncology. 20(12):1719-1729, 2019 12.
Institution: - MedStar Washington Hospital Center
Medline publication type:
All authors: - Blay JY, Chawla S, Choy E, Dai T, Gelderblom H, Grimer RJ, Henshaw R, Jandial D, Le Cesne A, Palmerini E, Reichardt P, Rutkowski P, Schuetze SM, Seeger L, Skubitz K
|
|
|
3.
|
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. MedStar authors:
Year: 2015
Citation: - Lancet Oncology. 16(9):1037-48, 2015 Sep.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Adams PT, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Liu Q, Mamounas EP, Margolese RG, Mehta RS, Paik S, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA
|
|
|
4.
|
|
|
|
5.
|
Radioiodine refractory differentiated thyroid cancer. [Review] MedStar authors:
Year: 2018
Citation: - Critical Reviews in Oncology-Hematology. 125:111-120, 2018 May.
Institution: - MedStar Washington Hospital Center
Department: - Medicine/Nuclear Medicine
Medline publication type:
All authors: - Chen L, Cheng L, Jin Y, Liu M, Van Nostrand D
|
|
|
6.
|
Decision-Making Analysis for Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: A Survey by the Executive Committee of the Peritoneal Surface Oncology Group International (PSOGI). MedStar authors:
Year: 2021
Citation: - Oncology. 99(1):41-48, 2021.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Bijelic L, de Hingh I, Glatzer M, Glehen O, Goere D, Haller L, Li Y, Moran BJ, Morris DL, Piso P, Putora PM, Quadros CA, Rau B, Steffen T, Sugarbaker P, Yonemura Y
|
|
|
7.
|
Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer. MedStar authors:
Year: 2014
Citation: - Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer. 9(1):121-5, 2014 Jan.
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase I
- Clinical Trial, Phase II
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Adams JW, Berger MS, Chiappori A, Edelman MJ, Haura EB, Malik S, Northfelt DW, Rosen P, Van Echo DA, Williams C
|
|
|
8.
|
|
|
|
9.
|
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. MedStar authors:
Year: 2017
Citation: - Clinical Breast Cancer. 17(1):48-54.e3, 2017 Feb
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Ansari B, Buyse ME, Conlin AK, Geyer CE Jr, Gross HM, Jacobs SA, Keogh GP, Lord RS, Mamounas EP, Mauquoi C, Patocskai EJ, Polikoff JA, Rastogi P, Robidoux A, Smith JW 2nd, Stella PJ, Swain SM, Wolmark N
|
